AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23731579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker shoe designs with varying apex angle
Number of subjects: 48
Study 23731579 — intervention group
Group type: COMPARATOR
Intervention: Control shoe (flexible)
Number of subjects: 48
Study 21383263 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (cognitive behavior therapy plus switch to a different antidepressant medication)
Number of subjects: 334
Study 20030546 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for two months
Number of subjects: 35
Study 20030546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 35
Study 16485749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lempel‐Ziv (LZ) complexity
Number of subjects: 40
Study 16485749 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate entropy (ApEn)
Number of subjects: 40
Study 16485749 — intervention group
Group type: EXPERIMENTAL
Intervention: Central tendency measure (CTM)
Number of subjects: 40
Study 15100917 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (IPR)
Number of subjects: 150
Study 15100917 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation (OPR)
Number of subjects: 150
Study 11096167 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening
Number of subjects: 46551
Study 11096167 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial screening
Number of subjects: 46551
Study 11096167 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 46551
Study 9574499 — intervention group
Group type: EXPERIMENTAL
Intervention: seven sessions of 1.5 hr each (10.5 hr)
Number of subjects: 151
Study 9574499 — intervention group
Group type: EXPERIMENTAL
Intervention: three sessions of 3.5 hr each (10.5 hr)
Number of subjects: 151
Study 9574499 — intervention group
Group type: COMPARATOR
Intervention: no-intervention condition
Number of subjects: 151
Study 7530706 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled substance P (SP) at doses of 0.25-8 mg/ml
Number of subjects: 9
Study 7530706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3414575 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus extract
Number of subjects: 20
Study 3414575 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (AA)
Number of subjects: 20
Study 3414575 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus extract ascorbate
Number of subjects: 20
Study 30230399 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis Ova (TSO) 2,500 ova every 2 weeks for 12 weeks
Number of subjects: 10
Study 30230399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30309257 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program adapted core weight loss program for 6 months
Number of subjects: 426
Study 30309257 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month maintenance treatment
Number of subjects: 426
Study 30309257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 426
Study 30309257 — intervention group
Group type: EXPERIMENTAL
Intervention: Church participation
Number of subjects: 426
Study 30309257 — intervention group
Group type: EXPERIMENTAL
Intervention: WL participation
Number of subjects: 426
Study 28618292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2.5mA, 15min)
Number of subjects: 26
Study 28618292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS (2.5mA, 15min)
Number of subjects: 26
Study 28618292 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 26
Study 25650104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-mA anodal tDCS
Number of subjects: 15
Study 25650104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-mA cathodal tDCS
Number of subjects: 15
Study 25650104 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 25650104 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 15
Study 24382221 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 40
Study 24382221 — intervention group
Group type: COMPARATOR
Intervention: Nondrainage
Number of subjects: 40
Study 21434488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/Paracetamol (TP 37.5/325 mg)
Number of subjects: 122
Study 21434488 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol/Codeine (CP 30/500 mg)
Number of subjects: 122
Study 19097715 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene (RLX)
Number of subjects: 52
Study 19097715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg percutaneous 17beta-estradiol associated to 60 mg raloxifene (RLX+E2)
Number of subjects: 52
Study 19097715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 52
Study 16597042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve circumcision of prepuce and coronary sulcus skin
Number of subjects: 69
Study 16597042 — intervention group
Group type: COMPARATOR
Intervention: Electric cauterization of verrucae plus general circumcision
Number of subjects: 69
Study 12775172 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the program (treatment group)
Number of subjects: 39
Study 12775172 — intervention group
Group type: COMPARATOR
Intervention: No access to program (control group)
Number of subjects: 39
Study 12529875 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation of cumulative probabilities
Number of subjects: 0
Study 12529875 — intervention group
Group type: COMPARATOR
Intervention: Traditional estimator of cumulative success probabilities
Number of subjects: 0
Study 10990237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for 12 weeks)
Number of subjects: 23
Study 10990237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8649699 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol
Number of subjects: 80
Study 8649699 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of vitamin B6
Number of subjects: 80
Study 1730840 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF)
Number of subjects: 0
Study 1730840 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen
Number of subjects: 0
Study 6150997 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version with tocolysis (ECV‐T) attempted
Number of subjects: 88
Study 6150997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ECV‐T attempted)
Number of subjects: 88
Study 6150997 — intervention group
Group type: COMPARATOR
Intervention: Failed ECV‐T
Number of subjects: 88
Study 6150997 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous conversion to cephalic presentations
Number of subjects: 88
Study 6150997 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications from ECV‐T
Number of subjects: 88
Study 3579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 19
Study 3579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered theophylline
Number of subjects: 19
Study 3579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled salbutamol and orally administered theophylline
Number of subjects: 19
Study 3579005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31962050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix and Gardasil (HPV vaccines)
Number of subjects: 12
Study 31255678 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 969
Study 31255678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969
Study 31255678 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 969
Study 31255678 — intervention group
Group type: COMPARATOR
Intervention: No treatment (absent depression)
Number of subjects: 969
Study 30580340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg thrice daily
Number of subjects: 72
Study 30580340 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (Control)
Number of subjects: 72
Study 25952634 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus gliclazide modified release combination therapy
Number of subjects: 105
Study 25952634 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin monotherapy
Number of subjects: 105
Study 25952634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 105
Study 23498848 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN1 (0.8 g/dL Orafti®Synergy1) supplemented infant formula
Number of subjects: 252
Study 23498848 — intervention group
Group type: COMPARATOR
Intervention: Control infant formula
Number of subjects: 252
Study 21256943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal sonic jet nebulizer (NJN)
Number of subjects: 7
Study 21256943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mesh nebulizer (NMN)
Number of subjects: 7
Study 19363624 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests (Villiger test, Oesch test, Biering‐Sørensen test)
Number of subjects: 162
Study 19363624 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 162
Study 16278686 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil (2.14 g of DHA/day)
Number of subjects: 27
Study 16278686 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (6 g)
Number of subjects: 27
Study 15596875 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol 340 (Niopam)
Number of subjects: 2019
Study 15596875 — intervention group
Group type: COMPARATOR
Intervention: iobitridol 350 (Xenetix)
Number of subjects: 2019
Study 11519638 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nicotine treatment
Number of subjects: 40
Study 11519638 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute nicotine treatment
Number of subjects: 40
Study 11519638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine treatment
Number of subjects: 40
Study 11519638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11519638 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 40
Study 9222944 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa
Number of subjects: 14
Study 9222944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline infusion
Number of subjects: 14
Study 9222944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7965876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% 2-6 ml/h infusion through a catheter placed in the sciatic or posterior tibial nerve sheath
Number of subjects: 59
Study 7965876 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonbupivacaine-treated patients)
Number of subjects: 59
Study 7965876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine treatment
Number of subjects: 59
Study 7965876 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 59
Study 3662562 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate in optimized vehicle (ointment)
Number of subjects: 38
Study 3662562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30724012 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy-style intervention including physical training and nutritional support (n=39)
Number of subjects: 80
Study 30724012 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 80
Study 28579313 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic soy milk (200 mL/day)
Number of subjects: 48
Study 28579313 — intervention group
Group type: COMPARATOR
Intervention: Soy milk (control)
Number of subjects: 48
Study 25300782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry
Number of subjects: 192
Study 25300782 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 192
Study 23682595 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure (>120/80 mmHg)
Number of subjects: 0
Study 23682595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (high BMI or waist circumference)
Number of subjects: 0
Study 23682595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia (low HDL-C, hypertriglyceridemia)
Number of subjects: 0
Study 21953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 21953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0
Study 18067552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program (20 sessions of 2 hours each) and medical care by a cardiologist
Number of subjects: 247
Study 18067552 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (control group)
Number of subjects: 247
Study 17211115 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil group (aromatherapy with lavender, ylangylang, and bergamot, once daily for 4 weeks)
Number of subjects: 52
Study 17211115 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 52
Study 17211115 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 17211115 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine levels among the three groups
Number of subjects: 52
Study 12845429 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mmol potassium phosphate in 50 ml saline over 2 h (Group 1)
Number of subjects: 47
Study 12845429 — intervention group
Group type: COMPARATOR
Intervention: 30 mmol potassium phosphate in 100 ml saline over 4 h (Group 2)
Number of subjects: 47
Study 12845429 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mmol potassium phosphate in 100 ml saline over 3 h (Group 3)
Number of subjects: 47
Study 12845429 — intervention group
Group type: COMPARATOR
Intervention: 45 mmol potassium phosphate in 100 ml saline over 6 h (Group 4)
Number of subjects: 47
Study 11282702 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session interpersonal-therapy-oriented group intervention
Number of subjects: 37
Study 11282702 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual condition
Number of subjects: 37
Study 9250849 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (10 mg/kg body weight, intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Number of subjects: 610
Study 9250849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Number of subjects: 610
Study 8413339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 79
Study 8413339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide plus Cisplatinum
Number of subjects: 79
Study 8413339 — intervention group
Group type: COMPARATOR
Intervention: Cisplatinum
Number of subjects: 79
Study 3787198 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium-YAG laser irradiation
Number of subjects: 122
Study 3787198 — intervention group
Group type: COMPARATOR
Intervention: TUR
Number of subjects: 122
Study 31556669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 95
Study 31556669 — intervention group
Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 95
Study 28720658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Number of subjects: 13299
Study 28720658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13299
Study 28720658 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2-90)
Number of subjects: 13299
Study 26227795 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich juice based on red grapes, cherries, chokeberries and bilberries
Number of subjects: 134
Study 26227795 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich juice enriched with polyphenol-rich extracts from blackcurrant press-residue
Number of subjects: 134
Study 26227795 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 134
Study 26227795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled juice group (both types of polyphenol-rich juices)
Number of subjects: 134
Study 23744427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metformin (3 g daily in three divided doses)
Number of subjects: 80
Study 23744427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21889078 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional brackets
Number of subjects: 20
Study 21889078 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 20
Study 21889078 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 20
Study 19401009 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle support
Number of subjects: 123
Study 19401009 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle support plus pedometer
Number of subjects: 123
Study 19401009 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study 19401009 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus pedometer
Number of subjects: 123
Study 19401009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 123
Study 16420274 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine retraction using 100 g sentalloy springs
Number of subjects: 10
Study 16420274 — intervention group
Group type: COMPARATOR
Intervention: Control canine (contralateral side)
Number of subjects: 10
Study 15530763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines (CPG) for assistive device use in home care
Number of subjects: 140
Study 15530763 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study 11117374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg) and Verapamil (120-240 mg)
Number of subjects: 18
Study 11117374 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10-20 mg)
Number of subjects: 18
Study 9315788 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled beta-agonist therapy
Number of subjects: 70
Study 9315788 — intervention group
Group type: COMPARATOR
Intervention: As-needed inhaled beta-agonist therapy
Number of subjects: 70
Study 8157042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (1 mg)
Number of subjects: 16
Study 8157042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (2 mg)
Number of subjects: 16
Study 8157042 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion glucagon
Number of subjects: 16
Study 8157042 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon
Number of subjects: 16
Study 2872870 — intervention group
Group type: EXPERIMENTAL
Intervention: Family treatment
Number of subjects: 103
Study 2872870 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 103
Study 2872870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of family treatment and social skills training
Number of subjects: 103
Study 2872870 — intervention group
Group type: COMPARATOR
Intervention: Drug-treated condition (Control)
Number of subjects: 103
Study 30513795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B-group vitamin supplementation
Number of subjects: 32
Study 26796916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for Balance Improvement Program (ExBP)
Number of subjects: 61
Study 26796916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61
Study 26796916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 61
Study 24717247 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper (desvenlafaxine 25 mg/d)
Number of subjects: 357
Study 24717247 — intervention group
Group type: COMPARATOR
Intervention: Abrupt discontinuation (placebo)
Number of subjects: 357
Study 24717247 — intervention group
Group type: EXPERIMENTAL
Intervention: No discontinuation (desvenlafaxine 50 mg/d)
Number of subjects: 357
Study 22939979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Programme (CBT)
Number of subjects: 133
Study 22939979 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 133
Study 22939979 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 133
Study 20445353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunotherapy treatment with rIL-2 and IFN-alpha
Number of subjects: 109
Study 20445353 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 109
Study 20445353 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL patients treated with immunotherapy
Number of subjects: 109
Study 20445353 — intervention group
Group type: EXPERIMENTAL
Intervention: HL patients
Number of subjects: 109
Study 17649770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (specifically zoledronate)
Number of subjects: 0
Study 15629825 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% gel twice daily (gel/gel)
Number of subjects: 353
Study 15629825 — intervention group
Group type: COMPARATOR
Intervention: 2% gel daily (evening, placebo/gel)
Number of subjects: 353
Study 15629825 — intervention group
Group type: COMPARATOR
Intervention: Vehicle twice daily (placebo/placebo)
Number of subjects: 353
Study 11973494 — intervention group
Group type: EXPERIMENTAL
Intervention: POM 1.0 mg/kg
Number of subjects: 129
Study 11973494 — intervention group
Group type: EXPERIMENTAL
Intervention: INM 0.4 mg/kg
Number of subjects: 129
Study 11973494 — intervention group
Group type: COMPARATOR
Intervention: POD 0.5 mg/kg
Number of subjects: 129
Study 10424986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth-generation multiple-step systems
Number of subjects: 48
Study 10424986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifth-generation single-bottle adhesives
Number of subjects: 48